RESUMO
AIM: To evaluate the efficacy and safety of foveal-sparing internal limiting membrane peeling(FSIP)or complete internal limiting membrane peeling(CMIP)for the treatment of myopic traction maculopathy(MTM)during vitrectomy.METHODS: CNKI, Wanfang, VIP, PubMed, Embase, Cochrane Library, and Web of Science were searched from January 1th 2000 to July 1th 2022, and studies that compared FSIP and CMIP for MTM were collected. The change and recovery rate of best corrected visual acuity(BCVA), incidence of full-thickness macular hole(FTMH), change of central foveal thickness(CFT)and the rate of complete reattachment.RESULTS: A total of 484 eyes from 12 literatures were included, with 203 eyes in the FSIP group and 281 eyes in the CMIP group. The results of Meta-analysis showed that FSIP group were superior to the CMIP group in the mean change of BCVA(SMD=0.52, 95%CI: 0.20～0.85, P=0.002), the improvement rate of BCVA(RR=1.50, 95%CI: 1.22～1.85, P=0.0002)and the incidence of postoperative FTMH(RR=0.23, 95%CI: 0.10～0.54, P=0.0008). There was no statistical difference between the two surgical methods in terms of mean change in CFT(SMD=0.04, 95%CI: -0.19～0.26, P=0.75)and the rate of complete reattachment(RR=1.12, 95%CI: 0.94～1.32, P=0.20).CONCLUSION: FSIP have similar anatomical outcomes compared to CMIP, but FSIP resulted in better visual acuity and lower incidence of postoperative FTMH.
RESUMO
Tonkinensis is commonly used in the treatment of hepatitis B infection in China with its effecttiveness in reducing clinical symptoms and improving liver function. However, the mechanism of the anti-HBV (hepatitis B virus) effect of Tonkinensis is still not clear. In this study, an integrative analysis using the network pharmacology and metabolomics was employed in identification of the main targets and mechanisms of Tonkinensis in treatment of HBV infections. First, the "drug-target" network was established by predicting the targets of the main chemical components of Tonkinensis; Secondly, the differential metabolites associated with the anti-HBV effect of Tonkinensis were analyzed with the LC-MS based metabolomics in HepG2.2.15 cells; Finally, the "drug ingredients-targets-metabolites" network was constructed to screen the main anti-HBV targets of Tonkinensis. The results suggest that Tonkinensis may act on 16 target proteins in the network of retinol metabolism, peroxisome proliferator activate-receptors (PPAR) signaling pathway and transcriptional regulation of cancer and so on, which contributed to the control of HBV replication and the regulation of immune function and metabolic disorders.